Physician profile
Callie B Hall
NPI 1083188387
$7,091.88
in general payments reported to CMS, 2019-2025
34 companies · $1,692 in 2025
The $1,692 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,543 · 2022: $676 · 2023: $2,166 · 2024: $1,016 · 2025: $1,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,873.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,009.97 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $908.38 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $747.65 | 2023-2025 | Freestyle Libre, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $502.27 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $446.99 | 2022-2025 | |
| Corcept Therapeutics | $441.17 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $353.79 | 2021-2023 | Farxiga |
| Dexcom, INC. | $342.47 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.06 | 2021-2023 | Cycloset |
| Amgen INC. | $291.12 | 2021-2025 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $245.94 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $212.77 | 2021-2023 | Steglujan, Steglatro, Segluromet |
| Abbvie INC. | $199.25 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $160.91 | 2021-2024 | Unithroid |
| Sanofi-Aventis U.S. LLC | $105.57 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $90.04 | 2021-2024 | |
| Amarin Pharma, INC. | $84.84 | 2021 | |
| Madrigal Pharmaceuticals | $78.29 | 2025 | Rezdiffra |
| Esperion Therapeutics, INC. | $62.83 | 2021 | |
| Xeris Pharmaceuticals, INC. | $59.13 | 2022-2023 | Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $58.14 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $53.65 | 2023-2025 | Yorvipath |
| Arbor Pharmaceuticals, INC. | $42.97 | 2021 | |
| Ibsa Pharma INC. | $42.72 | 2021-2025 | Flector, Licart, Tirosint |
| Recordati_rare_diseases_inc. | $40.53 | 2021-2022 | |
| Glaxosmithkline, LLC. | $39.72 | 2025 | Arexvy, Shingrix |
| Tolmar, INC. | $33.30 | 2024-2025 | Jatenzo |
| Teva Pharmaceuticals USA, INC. | $22.62 | 2023 | Austedo Xr |
| Sequel Med Tech, LLC | $21.97 | 2025 | Twiist |
| Eusa Pharma (US) LLC | $17.93 | 2022 | |
| Acerus Pharmaceuticals Corporation | $16.84 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.18 | 2021 | |
| Amryt Pharma Holdings LTD | $15.84 | 2023 | Mycapssa |
| Grt US Holding, INC. | $14.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Callie Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.